William J. Greenlee
Merck & Co.
331 Papers
5.6K Citations
William J. Greenlee is an academic researcher from Merck & Co.. The author has contributed to research in topics: Angiotensin II & Chemistry. The author has an hindex of 52, co-authored 326 publications. Previous affiliations of William J. Greenlee include Schering-Plough & United States Military Academy.
Chat about Author
Papers
Patent
N,N-diacylpiperazine tachykinin antagonists
Sander G. Mills,Richard J. Budhu,Conrad P. Dorn,William J. Greenlee,Malcolm MacCoss,Mu Tsu Wu +5 more
- 10 Dec 1992
TL;DR: In this paper, the authors describe a class of diacylpiperazines of general structure (STR1) which are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma.
30
Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators
Jun Qin,Wei Zhou,Xianhai Huang,Pawan Dhondi,Anandan Palani,Robert G. Aslanian,Zhaoning Zhu,William J. Greenlee,Mary Cohen-Williams,Nicholas Jones,Lynn A. Hyde,Lili Zhang +11 more
TL;DR: The synthesis and structure-activity relationship of a novel series of pyrazolopyridines represent a new class of γ-secretase modulators that demonstrate good in vitro potency in inhibiting Aβ42 production.
30
Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
Anandan Palani,Sherry Shapiro,John W. Clader,William J. Greenlee,David J. Blythin,Kathleen Cox,Nicole Wagner,Julie M. Strizki,Bahige M. Baroudy,Niya Dan +9 more
TL;DR: The separation and biological evaluation of rotamers as well as interconversion studies on rotamer of the authors' clinical candidate SCH 351125 are described.
29
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.
Anandan Palani,Ashwin U. Rao,Xia Chen,Xianhai Huang,Jing Su,Huadong Tang,Yuhua Huang,Jun Qin,Dong Xiao,Sylvia J. Degrado,Michael Sofolarides,Xiaohong Zhu,Zhidan Liu,Mckittrick Brian A,Wei Zhou,Robert G. Aslanian,William J. Greenlee,Boonlert Cheewatrakoolpong,Hongtao Zhang,Farley C,Jacquelynn J. Cook,Stan Kurowski,Qiu Li,van Heek M,Wang G,Yunsheng Hsieh,Fangbiao Li,Scott Greenfeder,Madhu Chintala +28 more
TL;DR: Structure-guided optimization of a series of C-5 alkyl substituents led to the discovery of a potent nicotinic acid receptor agonist SCH 900271 (33) with an EC50 of 2 nM in the hu-GPR109a assay.